Measurement of renal transit of gadopentetate dimeglumine with echo-planar MR imaging

Times of peak gadolinium concentration ([Gd]) after intravenous (IV) and left ventricular (LV) bolus injection of gadopentetate dimeglumine were determined in renal cortex and medulla in normal rabbits and in rabbits after saline load (overhydration) or hemorrhage (dehydration). Magnetic resonance images were obtained with echo-planar inversion-recovery sequences, and signal intensity-versus-time curves in cortical and medullary regions of interest were converted to [Gd]-versus-time curves. Cortical perfusion measured with microspheres demonstrated that the three physiologic states were significantly different. There were three separate [Gd] peaks in both the cortex and medulla as the bolus moved from one anatomic compartment to the next. The first cortical peak occurred sooner after LV than after IV bolus injection (P <.05) and later in dehydrated than in normal and overhydrated rabbits (P <.05). The first medullary peak always followed the first cortical peak by about 6–10 seconds and mirrored the cortical patterns. The second and third cortical peaks were consistent with proximal and distal tubular transit. These peaks similarly showed faster response to LV than IV injection and were delayed by hemorrhage. The authors conclude that quantitative physiologic information can be obtained with dynamic contrast-enhanced MR imaging of the kidney.     

MR imaging of soft-tissue masses: Role of gadopentetate dimeglumine

To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft-tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/ kg) of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions) of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft-tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).     

MR imaging of Hippel-Lindau disease: value of gadopentetate dimeglumine.

Hippel-Lindau disease is an autosomal dominant disorder characterized by tumors of the central nervous system and abdominal viscera. Frequent multisystem radiologic evaluation of persons at risk is desirable. Twenty-seven patients with Hippel-Lindau disease or a family history of the disease were examined with both unenhanced and gadopentetate dimeglumine-enhanced magnetic resonance (MR) imaging to study the usefulness of the contrast medium in the evaluation of these patients. The MR studies were correlated with computed tomographic (CT) scans in seven patients and cerebral angiograms in five. Twelve patients had hemangioblastomas in the brain, and eight of these patients also had spinal cord lesions (most were multiple), well demonstrated with gadopentetate dimeglumine. Contrast-enhanced MR imaging enabled detection of more central nervous system lesions and provided better delineation than unenhanced MR imaging, CT, or angiography. In addition, four patients with multiple renal cysts seen on CT scans and unenhanced MR images had enhancing lesions that were later proved to be renal cell carcinoma at angiography and/or surgery. Four patients had cystic lesions in the pancreas that did not enhance and were later proved to be pancreatic cysts. The authors conclude that gadopentetate dimeglumine-enhanced MR imaging appears to be a useful method for evaluating and following up patients with Hippel-Lindau disease.     

Rectal carcinoma: Prospective comparison of conventional and gadopentetate dimeglumine enhanced fat-suppressed MR imaging

The purpose of this study is to compare the usefulness of conventional MR imaging and gadopentetate dimeglumine enhanced fat-suppressed MR imaging for the depiction and staging of rectal carcinoma. Thirty-two patients were prospectively evaluated by MR imaging using a 1.5-T unit. Based on the results of a barium study and/or digital examination, a balloon catheter was inserted to the level of the lesion before examination. Both conventional T1- and T2-weighted images and gadopentetate dimeglumine enhanced fat-suppressed T1-weighted images were obtained for all patients. The kappa statistics were performed for the evaluation of interobserver agreement and the McNemar test was performed for the analysis of staging accuracy. When only T1- and T2-weighted images were used, 5 of 32 tumors were not detected and the extent of 18 of 32 tumors were unclear. However, when gadopentetate dimeglumine enhanced fat-suppressed imaging was added, 24 of 32 tumors were well defined and only one tumor was not detected. In determining the depth of invasion, the staging accuracy was 72% for conventional imaging and 68% for all images combined. There was no significant difference between with gadopentetate dimeglumine fat-suppressed imaging and conventional imaging (P > .05). Use of gadopentetate dimeglumine (fat-suppressed imaging) resulted in overestimation of muscular invasion, peri-rectal fat invasion, and adjacent organ invasion in 12 patients, whereas nine patients were overestimated without the use of gadopentetate dimeglumine. In the detection of metastatic lymph nodes, gadopentetate dimeglumine enhanced fat-suppressed imaging also was not useful. Tumor detection was excellent using gadopentetate dimeglumine enhanced fat-suppressed images. However, the accuracy of staging was not improved by obtaining such images.     

Laryngospasm after administration of gadopentetate dimeglumine.

Few serious adverse reactions associated with the use of gadopentetate dimeglumine in magnetic resonance imaging have been reported. The present case involves an 8-year-old girl who developed laryngospasm after administration of gadopentetate dimeglumine.     

Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system

This study compared the safety and tolerability of gadodiamide injection at the standard dose (0.1 mmol/kg) and at a higher dose (0.3 mmol/kg) in 289 patients participating in a parallel group multiple independent trial program. All patients had a known or suspected central nervous system lesion necessitating investigation with contrast mediumenhanced magnetic resonance imaging. Safety assessments were made before and after injection of the contrast medium, and 1 day later. No adverse events were judged to be related to gadodiamide injection, and only 3.5% of the patients in each dose group reported adverse events that had an uncertain relationship to the contrast medium; both doses were therefore well tolerated. Headache was the most frequently reported event (2%). There were no significant injection-related changes in neurologic status, laboratory test results, or vital signs. The data obtained indicate that the higher dose of gadodiamide injection is as safe and well tolerated as the standard dose.     

Axonal transport and MR imaging: Prospects for contrast agent development

Axonal transport plays a critical role in the physiology and pathology of neurons, yet there have been virtually no clinical tools for its evaluation in human subjects. A wide variety of molecules that can act as axonal transport facilitators have been discovered and, in many cases, used to deliver labels detectable with histologic methods. Recently a number of investigators have reported preliminary success in developing intraneural contrast agents based on various versions of dextran-coated magnetite that may render magnetic resonance imaging capable of depicting axonal transport. It is not yet clear whether any clinically useful agents will eventually be developed, but there has been considerable progress in identifying design factors for such a pharmaceutical agent.     

Effects of MR exposure at 1.5 T on early embryonic development of the chick

The potential teratogenicity of magnetic resonance (MR) field exposure on the early development of the chick embryo was examined. Eggs at four developmental stages within the first 42 hours of incubation were exposed to a static magnetic field of 1.5 T for 6 hours and to 64-MHz radio-frequency field pulses and a switched magnetic field gradient with an amplitude of 0.6 G/cm for 4 h. When the embryos were sacrificed shortly thereafter (at ±53 hours of incubation), the abnormality and mortality rates of exposed and unexposed (control) embryos in each of the developmental groups did not show a consistent pattern. When embryos were sacrificed on the 6th day of incubation, exposed embryos from all developmental groups showed a trend toward higher abnormality and mortality rates than their controls. More extensive studies are needed to confirm these findings.     

Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging

RATIONALE AND OBJECTIVES: This study compared gadopentetate dimeglumine (molecular weight, 0.5 kD), a standard contrast medium, and Gadomer-17 (apparent molecular weight, approximately 35 kD), a new, clinically applicable, large-molecular contrast medium, with respect to their microvascular characterizations of experimentally induced breast tumors at magnetic resonance (MR) imaging. MATERIALS AND METHODS: A spectrum of breast tumors, benign through highly malignant, was induced in Sprague-Dawley rats (n = 30) by intraperitoneal administration of N-ethyl-N-nitrosourea (ENU), a potent carcinogen. All animals underwent three-dimensional spoiled gradient-recalled MR imaging, with precontrast imaging and dynamic postcontrast imaging after injection of gadopentetate dimeglumine (0.1 mmol/kg) and Gadomer-17 (0.03 mmol/kg), administered in a random order at a 24-hour interval. Several microvascular parameters were compared: the endothelial transfer coefficient (K(PS)), a measure of microvascular permeability; the fractional plasma volume (fPV), and the plasma equivalent volume. Each MR imaging parameter was correlated with histopathologic findings. RESULTS: With Gadomer-17, the mean values for K(PS) and fPV were significantly greater in carcinomas than in fibroadenomas (P < .004 and .04, respectively). With gadopentetate dimeglumine, the mean values for fPV and PEV were significantly greater in carcinomas (P <. 004 and .02, respectively). Because of the high variability within both fibroadenoma and carcinoma groups, however, there were no significant correlations between K(PS), fPV, or PEV and histopathologic tumor grade as indicated by the Scarff-Bloom-Richardson score, for either agent. CONCLUSION: Although the K(PS) and fPV estimates obtained from dynamic MR imaging data with Gadomer-17 enhancement offer some potential for characterizing breast tumors, none of the quantitative microvascular parameters derived with either agent were significantly correlated with histopathologic tumor grade.     

口服静脉用钆喷替酸葡甲胺对MR胰胆管成像质量影响的研究

目的 选择出静脉用钆喷替酸葡甲胺(Gd-DTPA)作为MR胰胆管成像(MRCP)口服胃肠道阴性对比剂的最佳浓度及容量;评价口服Gd-DTPA对比剂在抑制胃肠道高信号、改善MRCP图像质量中的作用.方法 (1)体外实验:对不同浓度Gd-DTPA稀释液及温开水空白对照组行T1WI、T2WI、二维单层快速自旋回波(FSE)序列及三维半傅立叶单次激发快速自旋回波(HASTE)序列扫描,测量不同成像序列上的信号强度并计算增强率,选择出最佳浓度;(2)临床实验:分别配制不同容量的最佳浓度Gd-DTPA稀释液作为MRCP口服胃肠道阴性对比剂,选择出最佳容量;以最佳浓度和容量Gd-DTPA对比剂对24例临床疑有胰胆管病变的患者行口服前及口服后5～10、10～15 minMRCP扫描,分析图像质量.统计方法采用计算机软件包SPSS 10.0版,对实验结果进行方差分析.结果 T1WI上对照组均为低信号,Gd-DTPA浓度≤0.01 mol/L时为完全高信号;T2WI上对照组为明亮高信号,Gd-DTPA浓度≥0.015 mol/L为完全低信号;2D FSE单层MRCP图像上对照组为明亮高信号,Gd-DTPA浓度在0.0025～0.0300 mol/L之间均为低信号;3D HASTE MRCP图像上对照组为明亮高信号,Gd-DTPA浓度≥0.01 mol/L时为完全低信号;容量≥100 ml浓度为0.01 mol/L的Gd-DTPA对比剂对胃及十二指肠内液体高信号的抑制效果完全;24例患者口服100 ml浓度为0.01 mol/LGd-DTPA对比剂10～15 min后MRCP图像上肝内1、2、3级胆管、肝总管、胆囊、胆总管、胰管头、体、尾的平均等级分数(分别为3.63、3.46、3.08、3.71、3.87、3.88、3.79、3.71、3.50)略高于5～10 min的图像(分别为3.54、3.46、3.00、3.79、3.96、3.87、3.71、3.67、3.54),差异无统计学意义(P值均>0.05),而口服对比剂后肝内3级胆管、胆总管、胰管的等级分数明显高于口服对比剂前(分别为2.79、3.71、3.50、3.42、3.25),差异有统计学意义(F值分别为4.36、4.75、7.86、8.05、7.55,P值均<0.05).结论 100 ml浓度0.01 mol/L的Gd-DTPA对比剂能使胃及十二指肠内潴留液高信号抑制完全,可作为MRCP理想的胃肠道阴性对比剂;口服对比剂后5～10 min行MRCP扫描,图像质量效果最佳.     

Mn-DPDP–enhanced MR imaging of malignant liver lesions: Efficacy and safety in 20 patients

Twenty patients with malignant liver lesions underwent magnetic resonance (MR) imaging with manganese (II) DPDP [N,N′-dipyridoxylethylenediamine-N,N′-diacetate 5,5′-bis(phosphate)] to evaluate the safety and efficacy of the contrast agent. In two groups of 10 patients each, 5 μmol/kg Mn-DPDP was administered intravenously (3 mL/min) at a concentration of either 50 or 10 μmol/mL. T1- and T2-weighted images were obtained with a 1.5-T imager. Six patients reported a total of eight instances of side effects (flush, feeling of warmth, metallic taste) of which seven occured at the 50 μmol/mL concentration. A significant decrease in alkaline phosphatase levels 2 hours after injection was recorded. On T1-weighted images, the 10 μmol/mL formulation yielded significantly greater increases in contrast-to-noise ratio (79.8%–137.5%) than the 50 μmol/mL formulation (46.2%–86.6%). In a blinded reader study of 10 patients with one to five lesions each, no lesion was missed on Mn-DPDP–enhanced T1-weighted images; however, four false-positive foci were identified. The authors conclude that slow administration of 5 μmol/kg Mn-DPDP at a concentration of 10 μmol/mL is safe and efficient enough to proceed to further clinical trials.     

Differentiating between T1 and T2* changes caused by gadopentetate dimeglumine in the kidney by using a double-echo dynamic MR imaging sequence

Dynamic MR images of the passage of gadopentetate dimeglumine through the kidneys of normal rats are obtained using a dual gradient-echo sequence. The amplitudes of gradient echoes are defined by local T1 and T2* values in the tissue. The ratio of these amplitudes, primarily defined by local T2*, can be used to differentiate between T1 and T2* effects. This is particularly important with regard to renal studies because, due to a highly inhomogeneous distribution of gadopentetate dimeglumine in the kidney, T2* shortening can impede MR data analysis. To study changes in the observed signal caused by gadopentetate dimeglumine, curves of MR renal intensity versus time were obtained in the cortex and medulla after administration of the contrast agent. Using T2* compensation, distinct temporal peaks were observed in the cortex and outer medulla, indicating a high concentration of gadopentetate dimeglumine in the vascular phase. The authors conclude that this technique can be a useful tool for studying renal function noninvasively.     

Effect of field strength on gadolinium enhancement in MR imaging

This studv was designed to evaluate the influence of magnetic field strength on the relative enhancement effect (RE) of gadolinium (Gd)-chelates. Dilution series of two paramagnetic contrast agents (Gd-DTPA and Gd-DOTA) were examined in three commercially available MR systems. operating at different field strengths (02 T, 1. T, and 1.5 T). The RE was plotted against Gd concentration. The highest increases in signal intensity occurred with Gd concentrations of approximately L.0 mmol/L. No significant difference in RE was observed between MR systems ranging in field strength from 0.? T to 1.5 T. The RE of Gd-DTPA and Gd-DOTA was found to he equivalent.     

Contrast-enhanced MR imaging of the liver: Comparison between Gd-BOPTA and mangafodipir

The purpose of the study was to evaluate the MR contrast agents gadolinium benzyloxypropionictetro-acetate (Gd-BOPTA) and Mangafodipir for liver enhancement and the lesion-liver contrast on T1W spin-echo (SE) and gradient-recalled-echo (GRE) images. Fifty-one patients (three groups of 17 patients each) with known or suspected liver lesions were evaluated with T1W SE (300/12) and GRE (77-80/2.3-2.5/80°) images before and after intravenous (IV) Gd-BOPTA (0.1 or 0.05 mmol/kg) or Mangafodipir (5 μmol/kg) in phase II to III clinical trials. Quantitative analysis by calculating liver signal-to-noise ratio (SNR), lesion-liver contrast-to-noise ratio (CNR), and spleen-liver CNR was performed. Liver SNR and spleen-liver CNR were always significantly increased postcontrast. SNR was highest after application of 0.1 mmol/kg Gd-BOPTA (51.3 ± 3.6, P < .05). CNR was highest after Mangafodipir (?22.6 ± 2.7), but this was not significantly different from others (P = .07). Overall, GRE images were superior to SE images for SNR and CNR. Mangafodipir and Gd-BOPTA (0.1 mmol/kg) provide equal liver enhancement and lesion conspicuity postcontrast. By all criteria, contrast-enhanced T1-weighted GRE were comparable to SE images.     

Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

To determine whether gadobenate dimeglumine (BOPTA) will adequately enhance cirrhotic liver parenchyma, and to document the enhancement patterns in cirrhosis, 14 cirrhotic and 20 non-cirrhotic patients were evaluated before and 60–120 minutes after gadolinium-BOPTA. Proof of liver cirrhosis was biopsy (6), surgical resection (3), and clinical follow-up (5). Enhancement effects were compared quantitatively by determining the liver signal-to-noise ratio (SNR) and signal enhancement in both populations. Qualitatively assessment of the liver enhancement was performed and classified as homogeneous or heterogeneous. Quantitative analysis: cirrhotic liver parenchyma presented a higher increase in SNR values, relative to noncirrhotic liver parenchyma, on postcontrast images. Likewise the signal enhancement of cirrhotic liver parenchyma was superior to non-cirrhotic liver on T1-weighted SE images (P = .02) and in-phase GRE images (P < .001). There was no statistical difference on out-of-phase GRE images. Qualitative analysis: on T1-weighted SE postcontrast images, cirrhotic liver parenchyma showed a homogeneous enhancement in 7 patients and heterogeneous in 7. Whereas on GRE images, cirrhotic parenchyma showed heterogeneous enhancement in 9 patients and homogeneous in 5 patients. The heterogeneous enhancement was due to the presence of hypointense nodules in 7 patients and hyperintense nodules in 2 patients. In conclusion, our study has shown that the hepatobiliary contrast agent Gd-BOPTA is effective in the cirrhotic liver, demonstrating an increased liver enhancement compared with non-cirrhotic patients.     

Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas

The purpose of this study was to compare the diagnostic efficacy of double-dose 1.0-M gadobutrol with that of standard-dose 0.5-M gadopentetate dimeglumine for revealing small hypervascular hepatocellular carcinomas (HCCs). Twenty-three patients with 37 HCCs (mean size: 1.2 cm) that were diagnosed by histology (n = 13) or imaging findings (n = 10) underwent two separate 3D dynamic MRIs with 0.2 mmol/kg of gadobutrol and 0.1 mmol/kg of gadopentetate dimeglumine. Three observers interpreted both MRIs in terms of lesion detection using the alternative-free response receiver operating characteristic method and lesion-to-liver contrast using matched pairs analysis. The two MRIs were also compared quantitatively by measuring the signal-to-noise ratio (SNR) of the liver and lesion as well as the lesion-liver contrast-to-noise ratio (CNR). The SNR of the liver and lesion and lesion-liver CNR with gadobutrol were better than those with gadopentetate dimeglumine (p < 0.01). However, in terms of the diagnostic accuracy (mean Az for gadobutrol: 0.878, and mean Az for gadopentate dimeglumine: 0.873), the sensitivity (92.8%), positive predictive value (92.8% vs. 93.7%) and lesion-liver contrast, the two dynamic MRIs were equivalent. Gadobutrol showed a superior degree of enhancement for hypervascular HCC than did gadopentetate dimeglumine, but the diagnostic capabilities of the two agents for revealing HCCs were equivalent.     

Diagnostic value of gadopentetate dimeglumine for 1.5-T MR imaging of musculoskeletal masses: comparison with unenhanced T1- and T2-weighted imaging.

Three magnetic resonance (MR) imaging techniques (T1-weighted, T2-weighted, and T1-weighted gadopentetate dimeglumine--enhanced) were compared in 32 consecutive MR imaging studies of 26 patients with suspected musculoskeletal masses. T2-weighted images were superior to T1-weighted enhanced images with respect to detection and definition of lesions in 12% of cases (n = 4) and were equal in 88% of cases (n = 28). T2-weighted images were also superior to T1-weighted images in 38% of cases (n = 12). In no cases were T1-weighted enhanced images superior to T2-weighted images. In two cases, T1-weighted images were superior to both T1-weighted enhanced and T2-weighted images. The authors conclude that gadopentetate dimeglumine did not provide much value in lesion detection above that obtained with T2-weighted images. They also conclude that T1-weighted images were occasionally superior to T1-weighted enhanced images and T2-weighted images because of loss of definition between fat and lesion on the latter.     

Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine

PURPOSE: To compare intraindividually gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for multi-station MR Angiography of the run-off vessels. MATERIALS AND METHODS: Twenty-one randomized healthy volunteers received either Gd-BOPTA or Gd-DTPA as a first injection and then the other agent as a second injection after a minimum interval of 6 days. Each agent was administered at a dose of 0.1 mmol/kg bodyweight followed by a 25-mL saline flush at a single constant flow rate of 0.8 mL/second. Images were acquired sequentially at the level of the pelvis, thigh, and calf using a fast three-dimensional (3D) gradient echo sequence. Source, subtracted source, maximum intensity projection (MIP), and subtracted MIP image sets from each examination were evaluated quantitatively and qualitatively on a segmental basis involving nine vascular segments. RESULTS: Significantly (P < 0.05) higher signal-to-noise and contrast-to-noise ratios were noted for Gd-BOPTA compared to Gd-DTPA, with the more pronounced differences evident in the more distal vessels. Qualitative assessmentrevealed no differences in the abdominal vasculature, a preference for Gd-BOPTA in the pelvic vasculature, and markedly better performance for Gd-BOPTA in the femoral and tibial vasculature. Summation of individual diagnostic quality scores for each segment revealed a significantly (P = 0.0001) better performance for Gd-BOPTA compared to Gd-DTPA. CONCLUSION: Greater vascular enhancement of the run-off vasculature is obtained after Gd-BOPTA, particularly in the smaller more distal vessels. Enhancement differences are not merely dose dependent, but may be due to different vascular enhancement characteristics of the agents.